Logo image of MEDP

MEDPACE HOLDINGS INC (MEDP) Stock Fundamental Analysis

NASDAQ:MEDP - Nasdaq - US58506Q1094 - Common Stock - Currency: USD

305.11  +2.86 (+0.95%)

After market: 305.11 0 (0%)

Fundamental Rating

7

We assign a fundamental rating of 7 out of 10 to MEDP. MEDP was compared to 56 industry peers in the Life Sciences Tools & Services industry. Both the health and profitability get an excellent rating, making MEDP a very profitable company, without any liquidiy or solvency issues. MEDP is not valued too expensively and it also shows a decent growth rate. This makes MEDP very considerable for quality investing!


Dividend Valuation Growth Profitability Health

Quickly go to:

9

1. Profitability

1.1 Basic Checks

MEDP had positive earnings in the past year.
MEDP had a positive operating cash flow in the past year.
In the past 5 years MEDP has always been profitable.
In the past 5 years MEDP always reported a positive cash flow from operatings.
MEDP Yearly Net Income VS EBIT VS OCF VS FCFMEDP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

1.2 Ratios

The Return On Assets of MEDP (21.95%) is better than 98.21% of its industry peers.
With an excellent Return On Equity value of 70.14%, MEDP belongs to the best of the industry, outperforming 98.21% of the companies in the same industry.
With an excellent Return On Invested Capital value of 49.81%, MEDP belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for MEDP is significantly above the industry average of 12.86%.
The last Return On Invested Capital (49.81%) for MEDP is above the 3 year average (38.75%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 21.95%
ROE 70.14%
ROIC 49.81%
ROA(3y)18.14%
ROA(5y)15.16%
ROE(3y)54.33%
ROE(5y)40%
ROIC(3y)38.75%
ROIC(5y)29.27%
MEDP Yearly ROA, ROE, ROICMEDP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60

1.3 Margins

MEDP has a better Profit Margin (19.31%) than 96.43% of its industry peers.
MEDP's Profit Margin has improved in the last couple of years.
The Operating Margin of MEDP (21.16%) is better than 89.29% of its industry peers.
In the last couple of years the Operating Margin of MEDP has grown nicely.
MEDP has a Gross Margin of 31.51%. This is in the lower half of the industry: MEDP underperforms 73.21% of its industry peers.
MEDP's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 21.16%
PM (TTM) 19.31%
GM 31.51%
OM growth 3Y6.82%
OM growth 5Y7.46%
PM growth 3Y6.48%
PM growth 5Y10.5%
GM growth 3Y2.7%
GM growth 5Y1.75%
MEDP Yearly Profit, Operating, Gross MarginsMEDP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 20 30 40

More info and screens

8

2. Health

2.1 Basic Checks

MEDP has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
The number of shares outstanding for MEDP has been reduced compared to 1 year ago.
Compared to 5 years ago, MEDP has less shares outstanding
MEDP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
MEDP Yearly Shares OutstandingMEDP Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
MEDP Yearly Total Debt VS Total AssetsMEDP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

An Altman-Z score of 5.58 indicates that MEDP is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 5.58, MEDP belongs to the best of the industry, outperforming 87.50% of the companies in the same industry.
There is no outstanding debt for MEDP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 5.58
ROIC/WACC4.82
WACC10.34%
MEDP Yearly LT Debt VS Equity VS FCFMEDP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.3 Liquidity

MEDP has a Current Ratio of 0.73. This is a bad value and indicates that MEDP is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 0.73, MEDP is doing worse than 94.64% of the companies in the same industry.
MEDP has a Quick Ratio of 0.73. This is a bad value and indicates that MEDP is not financially healthy enough and could expect problems in meeting its short term obligations.
MEDP's Quick ratio of 0.73 is on the low side compared to the rest of the industry. MEDP is outperformed by 91.07% of its industry peers.
The current and quick ratio evaluation for MEDP is rather negative, while it does have excellent solvency and profitability. These ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
Industry RankSector Rank
Current Ratio 0.73
Quick Ratio 0.73
MEDP Yearly Current Assets VS Current LiabilitesMEDP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 33.54% over the past year.
The Earnings Per Share has been growing by 33.22% on average over the past years. This is a very strong growth
MEDP shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 9.87%.
The Revenue has been growing by 19.62% on average over the past years. This is quite good.
EPS 1Y (TTM)33.54%
EPS 3Y37.96%
EPS 5Y33.22%
EPS Q2Q%14.69%
Revenue 1Y (TTM)9.87%
Revenue growth 3Y22.68%
Revenue growth 5Y19.62%
Sales Q2Q%9.3%

3.2 Future

MEDP is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 9.55% yearly.
MEDP is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 9.29% yearly.
EPS Next Y-0.92%
EPS Next 2Y4.48%
EPS Next 3Y7.26%
EPS Next 5Y9.55%
Revenue Next Year3.4%
Revenue Next 2Y3.5%
Revenue Next 3Y5.42%
Revenue Next 5Y9.29%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
MEDP Yearly Revenue VS EstimatesMEDP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 1B 2B 3B 4B
MEDP Yearly EPS VS EstimatesMEDP Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 5 10 15 20 25

More info and screens

5

4. Valuation

4.1 Price/Earnings Ratio

MEDP is valuated rather expensively with a Price/Earnings ratio of 23.29.
73.21% of the companies in the same industry are more expensive than MEDP, based on the Price/Earnings ratio.
MEDP is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 28.22, which is the current average of the S&P500 Index.
The Price/Forward Earnings ratio is 22.13, which indicates a rather expensive current valuation of MEDP.
73.21% of the companies in the same industry are more expensive than MEDP, based on the Price/Forward Earnings ratio.
Compared to an average S&P500 Price/Forward Earnings ratio of 20.86, MEDP is valued at the same level.
Industry RankSector Rank
PE 23.29
Fwd PE 22.13
MEDP Price Earnings VS Forward Price EarningsMEDP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of MEDP indicates a rather cheap valuation: MEDP is cheaper than 82.14% of the companies listed in the same industry.
89.29% of the companies in the same industry are more expensive than MEDP, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 16.21
EV/EBITDA 17.15
MEDP Per share dataMEDP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40 60

4.3 Compensation for Growth

The excellent profitability rating of MEDP may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.7
EPS Next 2Y4.48%
EPS Next 3Y7.26%

More info and screens

0

5. Dividend

5.1 Amount

MEDP does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MEDPACE HOLDINGS INC

NASDAQ:MEDP (5/2/2025, 8:09:10 PM)

After market: 305.11 0 (0%)

305.11

+2.86 (+0.95%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)04-21 2025-04-21/amc
Earnings (Next)07-21 2025-07-21/amc
Inst Owners84.94%
Inst Owner Change0.14%
Ins Owners0.5%
Ins Owner Change6.32%
Market Cap8.77B
Analysts70.59
Price Target313.07 (2.61%)
Short Float %8.51%
Short Ratio3.8
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)19.63%
Min EPS beat(2)17.65%
Max EPS beat(2)21.62%
EPS beat(4)4
Avg EPS beat(4)12.94%
Min EPS beat(4)6.19%
Max EPS beat(4)21.62%
EPS beat(8)7
Avg EPS beat(8)11.59%
EPS beat(12)11
Avg EPS beat(12)14.85%
EPS beat(16)15
Avg EPS beat(16)14.74%
Revenue beat(2)1
Avg Revenue beat(2)1.13%
Min Revenue beat(2)-1.63%
Max Revenue beat(2)3.88%
Revenue beat(4)1
Avg Revenue beat(4)-0.79%
Min Revenue beat(4)-3.35%
Max Revenue beat(4)3.88%
Revenue beat(8)3
Avg Revenue beat(8)-0.22%
Revenue beat(12)7
Avg Revenue beat(12)0.8%
Revenue beat(16)8
Avg Revenue beat(16)0.4%
PT rev (1m)-12.37%
PT rev (3m)-12.09%
EPS NQ rev (1m)-2%
EPS NQ rev (3m)-1.71%
EPS NY rev (1m)-0.52%
EPS NY rev (3m)-2.58%
Revenue NQ rev (1m)0.71%
Revenue NQ rev (3m)-1.43%
Revenue NY rev (1m)0.86%
Revenue NY rev (3m)-2.16%
Valuation
Industry RankSector Rank
PE 23.29
Fwd PE 22.13
P/S 4.07
P/FCF 16.21
P/OCF 15.07
P/B 14.77
P/tB N/A
EV/EBITDA 17.15
EPS(TTM)13.1
EY4.29%
EPS(NY)13.79
Fwd EY4.52%
FCF(TTM)18.82
FCFY6.17%
OCF(TTM)20.25
OCFY6.64%
SpS75.04
BVpS20.65
TBVpS-3.58
PEG (NY)N/A
PEG (5Y)0.7
Profitability
Industry RankSector Rank
ROA 21.95%
ROE 70.14%
ROCE 58.88%
ROIC 49.81%
ROICexc 115.73%
ROICexgc N/A
OM 21.16%
PM (TTM) 19.31%
GM 31.51%
FCFM 25.08%
ROA(3y)18.14%
ROA(5y)15.16%
ROE(3y)54.33%
ROE(5y)40%
ROIC(3y)38.75%
ROIC(5y)29.27%
ROICexc(3y)71.87%
ROICexc(5y)52.56%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)47.22%
ROCE(5y)35.45%
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3Y64.05%
ROICexc growth 5Y48.31%
OM growth 3Y6.82%
OM growth 5Y7.46%
PM growth 3Y6.48%
PM growth 5Y10.5%
GM growth 3Y2.7%
GM growth 5Y1.75%
F-Score8
Asset Turnover1.14
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 140.62%
Cap/Sales 1.9%
Interest Coverage 250
Cash Conversion 119.87%
Profit Quality 129.91%
Current Ratio 0.73
Quick Ratio 0.73
Altman-Z 5.58
F-Score8
WACC10.34%
ROIC/WACC4.82
Cap/Depr(3y)142.96%
Cap/Depr(5y)144.54%
Cap/Sales(3y)2.07%
Cap/Sales(5y)2.41%
Profit Quality(3y)141.71%
Profit Quality(5y)142.32%
High Growth Momentum
Growth
EPS 1Y (TTM)33.54%
EPS 3Y37.96%
EPS 5Y33.22%
EPS Q2Q%14.69%
EPS Next Y-0.92%
EPS Next 2Y4.48%
EPS Next 3Y7.26%
EPS Next 5Y9.55%
Revenue 1Y (TTM)9.87%
Revenue growth 3Y22.68%
Revenue growth 5Y19.62%
Sales Q2Q%9.3%
Revenue Next Year3.4%
Revenue Next 2Y3.5%
Revenue Next 3Y5.42%
Revenue Next 5Y9.29%
EBIT growth 1Y28.65%
EBIT growth 3Y31.04%
EBIT growth 5Y28.55%
EBIT Next Year10.98%
EBIT Next 3Y11.17%
EBIT Next 5Y12.73%
FCF growth 1Y40.57%
FCF growth 3Y34.54%
FCF growth 5Y25.47%
OCF growth 1Y37.94%
OCF growth 3Y32.23%
OCF growth 5Y24.7%